Literature DB >> 28480201

Radical local therapy in combination with standard treatment for oligometastatic stage IV non-small-cell lung cancer.

Hironori Yoshida1, Young Hak Kim1.   

Abstract

Entities:  

Year:  2017        PMID： 28480201      PMCID： PMC5401675          DOI： 10.21037/atm.2017.03.56

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  13 in total

Review 1.  Surgical treatment of oligometastatic non-small cell lung cancer.

Authors:  Joachim Pfannschmidt; Hendrik Dienemann
Journal:  Lung Cancer       Date:  2010-09       Impact factor: 5.705

2.  Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer.

Authors:  Puneeth Iyengar; Brian D Kavanagh; Zabi Wardak; Irma Smith; Chul Ahn; David E Gerber; Jonathan Dowell; Randall Hughes; Ramzi Abdulrahman; D Ross Camidge; Laurie E Gaspar; Robert C Doebele; Paul A Bunn; Hak Choy; Robert Timmerman
Journal:  J Clin Oncol       Date:  2014-10-27       Impact factor: 44.544

Review 3.  Is there an oligometastatic state in non-small cell lung cancer? A systematic review of the literature.

Authors:  Allison Ashworth; George Rodrigues; Gabriel Boldt; David Palma
Journal:  Lung Cancer       Date:  2013-08-20       Impact factor: 5.705

4.  First-line crizotinib versus chemotherapy in ALK-positive lung cancer.

Authors:  Benjamin J Solomon; Tony Mok; Dong-Wan Kim; Yi-Long Wu; Kazuhiko Nakagawa; Tarek Mekhail; Enriqueta Felip; Federico Cappuzzo; Jolanda Paolini; Tiziana Usari; Shrividya Iyer; Arlene Reisman; Keith D Wilner; Jennifer Tursi; Fiona Blackhall
Journal:  N Engl J Med       Date:  2014-12-04       Impact factor: 91.245

5.  Survival of patients treated surgically for synchronous single-organ metastatic NSCLC and advanced pathologic TN stage.

Authors:  Stéphane Collaud; Rolf Stahel; Ilhan Inci; Sven Hillinger; Didier Schneiter; Peter Kestenholz; Walter Weder
Journal:  Lung Cancer       Date:  2012-10-03       Impact factor: 5.705

6.  Radical treatment of non-small-cell lung cancer patients with synchronous oligometastases: long-term results of a prospective phase II trial (Nct01282450).

Authors:  Dirk De Ruysscher; Rinus Wanders; Angela van Baardwijk; Anne-Marie C Dingemans; Bart Reymen; Ruud Houben; Gerben Bootsma; Cordula Pitz; Linda van Eijsden; Wiel Geraedts; Brigitta G Baumert; Philippe Lambin
Journal:  J Thorac Oncol       Date:  2012-10       Impact factor: 15.609

7.  Stereotactic body radiotherapy for oligometastatic lung tumors.

Authors:  Yoshiki Norihisa; Yasushi Nagata; Kenji Takayama; Yukinori Matsuo; Takashi Sakamoto; Masato Sakamoto; Takashi Mizowaki; Shinsuke Yano; Masahiro Hiraoka
Journal:  Int J Radiat Oncol Biol Phys       Date:  2008-04-18       Impact factor: 7.038

8.  A randomized phase III trial of stereotactic radiosurgery (SRS) versus observation for patients with asymptomatic cerebral oligo-metastases in non-small-cell lung cancer.

Authors:  S H Lim; J Y Lee; M-Y Lee; H S Kim; J Lee; J-M Sun; J S Ahn; S-W Um; H Kim; B S Kim; S T Kim; D L Na; J Y Sun; S H Jung; K Park; O J Kwon; J-I Lee; M-J Ahn
Journal:  Ann Oncol       Date:  2014-12-23       Impact factor: 32.976

9.  Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study.

Authors:  Daniel R Gomez; George R Blumenschein; J Jack Lee; Mike Hernandez; Rong Ye; D Ross Camidge; Robert C Doebele; Ferdinandos Skoulidis; Laurie E Gaspar; Don L Gibbons; Jose A Karam; Brian D Kavanagh; Chad Tang; Ritsuko Komaki; Alexander V Louie; David A Palma; Anne S Tsao; Boris Sepesi; William N William; Jianjun Zhang; Qiuling Shi; Xin Shelley Wang; Stephen G Swisher; John V Heymach
Journal:  Lancet Oncol       Date:  2016-10-24       Impact factor: 41.316

Review 10.  Oligometastases and oligo-recurrence: the new era of cancer therapy.

Authors:  Yuzuru Niibe; Kazushige Hayakawa
Journal:  Jpn J Clin Oncol       Date:  2010-01-04       Impact factor: 3.019
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.